Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Wednesday, January 29, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has announced key promotions within its leadership team, including Cindy Atwell as Chief Development and Business Officer and Cassie Gorsuch, PhD, as Chief Scientific Officer. These changes aim to bolster the company's efforts in advancing multiple in vivo gene editing programs. The leadership enhancements reflect Precision's commitment to innovation and growth in the gene editing sector.
Price reaction · baseline $5.04 (2025-01-28 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Promotions of key leadership roles enhance company strategy.
  • Strengthening the leadership team signals growth potential.
  • Focus on in vivo gene editing programs indicates innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

– Cindy Atwell , promoted to Chief Development and Business Officer- – Cassie Gorsuch , PhD, promoted to Chief Scientific Officer – DURHAM, N.C. –(BUSINESS WIRE)–Jan. 29, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS

Frequently Asked Questions

Who were promoted at Precision BioSciences?

Cindy Atwell was promoted to Chief Development and Business Officer, and Cassie Gorsuch, PhD, became Chief Scientific Officer.

What is the focus of Precision BioSciences?

The company focuses on advancing multiple in vivo gene editing programs.

Why are leadership changes significant?

These changes aim to strengthen the company's strategy and drive innovation in gene editing.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing Cindy Atwell Cassie Gorsuch
Last updated: Jan 29, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →